Micro Cap Ideas

[gfp927z]

>>> Simulations Plus (SLP) is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed and used for drug research by major pharmaceutical and biotechnology companies worldwide.


https://finance.yahoo.com/news/4-low-beta-tech-stocks-143202937.html


Currently, Simulations Plus has a Zacks Rank #2. It has a beta of 0.54. Shares of SLP have climbed 15.9% YTD.

Lancaster, CA-headquartered SLP’s performance is being driven by strength in its Services revenues, which increased 4% to $5.3 million in second-quarter fiscal 2023. In March, the company partnered with the Sino-American Cancer Foundation to boost the development of anticancer therapies. Earlier in the same month, it collaborated with the Institute of Medical Biology of the Polish Academy of Sciences to design new compounds for the ROR?/ROR?T nuclear receptors. As part of the agreement, the company is leveraging artificial intelligence/machine learning technologies in the ADMET Predictor platform for the development of new compounds.

The Zacks Consensus Estimate for SLP’s fiscal 2023 earnings is pegged at 66 cents, unchanged over the past seven days. The consensus mark for fiscal 2024 earnings has also remained steady for the past seven days at 71 cents, suggesting an 8.3% year-on-year rise.

<<<



---